European Journal of Biomedical and Pharmaceutical Sciences

DETERMINATION OF PSEUDOURIDINE IN SERUM AND SALIVA OF PRIMARY BRAIN TUMOR PATIENTS BY USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

*Abdul-Wahab R. Hamad, Walid W. Al-Rawi, Abdul-Rahman A. Al-Bazaz and Ameer A. Ameer

ABSTRACT

Background: Pseudouridine is a modified nucleoside derived from the degradation of some species of Ribonuclic acid (RNA), primarily transfer RNA, the level of which is elevated in biological fluids of tumor bearing subjects. This study was first done to measure Pseudouridine in serum and saliva of primary brain tumor patients. Aims of study: A case-control study designed to measure the levels of pseudouridine in serum and saliva of PBT patients. A prospective study designed to measure the levels of pseudouridine in serum and saliva of primary brain tumor (PBT) patients. Materials and Methods: This study had been conducted between November 2014 and October 2015. Employed in this study, in addition to the forty normal subjects used as controls, there were one hundred seven patients diagnosed clinically and histologically as having PBT. Their ages were between 2-75 years, (mean 35, the standard SD ± 19), 56 were males (52.33%), and 51 were females (47.67%). The most affected age group was 31-40 years (17.75%), 89% of the patients were under the age of 60 years. Histological typing: 44 gliomas and 32meningioma’s. Results: Mean levels of pseudouridine in serum and saliva of PBT patients, were significantly higher (p < 0.01) than its levels in normal. Conclusions and recommendations: Levels of pseudouridine in serum and saliva can be an extra tool in the investigation of PBT patients; however, both the specificity and sensitivity need to be ascertained.

Keywords: Primary brain tuours, pseudouridine, saliva, serum.